405 related articles for article (PubMed ID: 27081843)
1. Urinary microRNA-based signature improves accuracy of detection of clinically relevant prostate cancer within the prostate-specific antigen grey zone.
Salido-Guadarrama AI; Morales-Montor JG; Rangel-Escareño C; Langley E; Peralta-Zaragoza O; Cruz Colin JL; Rodriguez-Dorantes M
Mol Med Rep; 2016 Jun; 13(6):4549-60. PubMed ID: 27081843
[TBL] [Abstract][Full Text] [Related]
2. Development of a Whole-urine, Multiplexed, Next-generation RNA-sequencing Assay for Early Detection of Aggressive Prostate Cancer.
Cani AK; Hu K; Liu CJ; Siddiqui J; Zheng Y; Han S; Nallandhighal S; Hovelson DH; Xiao L; Pham T; Eyrich NW; Zheng H; Vince R; Tosoian JJ; Palapattu GS; Morgan TM; Wei JT; Udager AM; Chinnaiyan AM; Tomlins SA; Salami SS
Eur Urol Oncol; 2022 Aug; 5(4):430-439. PubMed ID: 33812851
[TBL] [Abstract][Full Text] [Related]
3. The Role of Urinary miRNAs in the Diagnosis, Management and Follow- Up of Prostatic Cancer.
Ziogou A; Giannakodimos A; Giannakodimos I
Microrna; 2023; 12(2):83-86. PubMed ID: 36999432
[TBL] [Abstract][Full Text] [Related]
4. Novel non-invasive biomarkers that distinguish between benign prostate hyperplasia and prostate cancer.
Jedinak A; Curatolo A; Zurakowski D; Dillon S; Bhasin MK; Libermann TA; Roy R; Sachdev M; Loughlin KR; Moses MA
BMC Cancer; 2015 Apr; 15():259. PubMed ID: 25884438
[TBL] [Abstract][Full Text] [Related]
5.
Zniber M; Lamminen T; Taimen P; Boström PJ; Huynh TP
Heliyon; 2024 Apr; 10(7):e28949. PubMed ID: 38617934
[TBL] [Abstract][Full Text] [Related]
6. The Diagnostic Value of Serum TGF-β1, p2PSA Combined with PSA in Prostate Cancer.
Guo X; Sun X; Ye P
Altern Ther Health Med; 2023 Nov; ():. PubMed ID: 37971439
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of miR-148a-3p and miR-106a-5p as Biomarkers for Prostate Cancer: Pilot Study.
Coman RA; Schitcu VH; Budisan L; Raduly L; Braicu C; Petrut B; Coman I; Berindan-Neagoe I; Al Hajjar N
Genes (Basel); 2024 May; 15(5):. PubMed ID: 38790213
[TBL] [Abstract][Full Text] [Related]
8. CHRDL1, NEFH, TAGLN and SYNM as novel diagnostic biomarkers of benign prostatic hyperplasia and prostate cancer.
Su Z; Wang G; Li L
Cancer Biomark; 2023; 38(2):143-159. PubMed ID: 37781794
[TBL] [Abstract][Full Text] [Related]
9. Clinical evaluation of prostate cancer gene 3 score in diagnosis among Chinese men with prostate cancer and benign prostatic hyperplasia.
Huang J; Reilly KH; Zhang HZ; Wang HB
BMC Urol; 2015 Dec; 15():118. PubMed ID: 26628213
[TBL] [Abstract][Full Text] [Related]
10. Metabolic Syndrome is Associated with Prostate Cancer Diagnosed on Biopsy but not the Gleason Score and the Number of Cancer-Positive Cores: A Prospective Controlled Study.
Bayraktar Z; Şahin C; Yıldırım S; Karaca Y; Sinanoğlu O
Arch Esp Urol; 2023 Sep; 76(7):504-510. PubMed ID: 37867335
[TBL] [Abstract][Full Text] [Related]
11. Deregulation of miR-10b and miR-21 Correlate with Cancer Stem Cells Expansion through the Apoptotic Pathway in Prostate Cancer.
Shukla KK; Choudhary GR; Sankanagoudar S; Misra S; Vishnoi JR; Pareek P; Pilla KK; Pandey SN; Sharma P
Asian Pac J Cancer Prev; 2023 Jun; 24(6):2105-2119. PubMed ID: 37378942
[TBL] [Abstract][Full Text] [Related]
12. Predicting Positive Repeat Prostate Biopsy Outcomes: Comparison of Machine Learning Approaches to Identify Key Parameters and Optimal Algorithms.
Zhang X; Feng C; Bai X; Peng X; Guo Q; Chen L; Xue J
Arch Esp Urol; 2023 Sep; 76(7):494-503. PubMed ID: 37867334
[TBL] [Abstract][Full Text] [Related]
13. Development of a predictive model to distinguish prostate cancer from benign prostatic hyperplasia by integrating serum glycoproteomics and clinical variables.
Gabriele C; Aracri F; Prestagiacomo LE; Rota MA; Alba S; Tradigo G; Guzzi PH; Cuda G; Damiano R; Veltri P; Gaspari M
Clin Proteomics; 2023 Nov; 20(1):52. PubMed ID: 37990292
[TBL] [Abstract][Full Text] [Related]
14. Neutrophil gelatinase-associated lipocalin as a screening test in prostate cancer.
Muşlu N; Ercan B; Akbayır S; Balcı Ş; Ovla HD; Bozlu M
Turk J Urol; 2017 Mar; 43(1):30-35. PubMed ID: 28270948
[TBL] [Abstract][Full Text] [Related]
15. ProsTAV, a novel blood-based test for biopsy decision management in significant prostate cancer.
Gómez Gómez E; Cano Castiñeira R; Burgos J; Rodríguez Antolín A; Miles BJ; Martínez Salamanca JI; Bianco F; Fernández L; Calmarza I; Pastor J; Butler RG; de Pedro N
Prostate; 2023 Oct; 83(14):1323-1331. PubMed ID: 37409738
[TBL] [Abstract][Full Text] [Related]
16. Combination of three miRNA (miR-141, miR-21, and miR-375) as potential diagnostic tool for prostate cancer recognition.
Porzycki P; Ciszkowicz E; Semik M; Tyrka M
Int Urol Nephrol; 2018 Sep; 50(9):1619-1626. PubMed ID: 30014459
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of micro-RNA in extracellular vesicles from blood of patients with prostate cancer.
Kim J; Cho S; Park Y; Lee J; Park J
PLoS One; 2021; 16(12):e0262017. PubMed ID: 34972164
[TBL] [Abstract][Full Text] [Related]
18. Non‑invasive prostate cancer detection by measuring miRNA variants (isomiRs) in urine extracellular vesicles.
Koppers-Lalic D; Hackenberg M; de Menezes R; Misovic B; Wachalska M; Geldof A; Zini N; de Reijke T; Wurdinger T; Vis A; van Moorselaar J; Pegtel M; Bijnsdorp I
Oncotarget; 2016 Apr; 7(16):22566-78. PubMed ID: 26992225
[TBL] [Abstract][Full Text] [Related]
19. Development and Validation of an 18-Gene Urine Test for High-Grade Prostate Cancer.
Tosoian JJ; Zhang Y; Xiao L; Xie C; Samora NL; Niknafs YS; Chopra Z; Siddiqui J; Zheng H; Herron G; Vaishampayan N; Robinson HS; Arivoli K; Trock BJ; Ross AE; Morgan TM; Palapattu GS; Salami SS; Kunju LP; Tomlins SA; Sokoll LJ; Chan DW; Srivastava S; Feng Z; Sanda MG; Zheng Y; Wei JT; Chinnaiyan AM;
JAMA Oncol; 2024 Apr; ():. PubMed ID: 38635241
[TBL] [Abstract][Full Text] [Related]
20. Filamin A Is a Prognostic Serum Biomarker for Differentiating Benign Prostatic Hyperplasia from Prostate Cancer in Caucasian and African American Men.
Mahaveer Chand N; Tekumalla PK; Rosenberg MT; Dobi A; Ali A; Miller GM; Aristizabal-Henao JJ; Granger E; Freedland SJ; Kellogg MD; Srivastava S; McLeod DG; Narain NR; Kiebish MA
Cancers (Basel); 2024 Feb; 16(4):. PubMed ID: 38398103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
